Journal article

Treatment Options for H5N1: Lessons Learned From the H1N1 Pandemic

Phillip Andrew Reece

POSTGRADUATE MEDICINE | TAYLOR & FRANCIS LTD | Published : 2010

Abstract

Human infections with avian influenza A (H5N1) are relatively rare but are associated with high mortality. As of July 5, 2010 there had been 500 cases and 296 fatalities. The influenza virus readily undergoes mutation and reassortment, and there are concerns that an H5N1 variant could be responsible for a future pandemic. The influenza neuraminidase inhibitors zanamivir and oseltamivir are approved for the treatment and prophylaxis of influenza. Oseltamivir is being used to treat H5N1 infections and the case has been made for a role for zanamivir; however, there are no case reports for the latter. Zanamivir is a potent inhibitor of H5N1, attains high lung concentrations immediately on admini..

View full abstract

University of Melbourne Researchers